Summary:
The SOPHIA study is a Phase III research study that is currently evaluating the safety and effectiveness of a new investigational medication for the treatment of HER2-positive metastatic breast cancer. It is a study designed to evaluate new treatment possibilities to support those with the unique diagnosis of HER2-positive metastatic breast cancer.
Qualified study participants will receive:
- Chemotherapy in combination with either an investigational monoclonal antibody that targets HER2 or Herceptin® (trastuzumab) at no cost
- Study-related exams and evaluations at no cost
Participants may be reimbursed for necessary travel expenses, overnight lodging, and/or meals associated with being in the study.
Qualified Participants Must:
• have received at least 1 treatment with medication (chemotherapy or targeted agent), but no more than 3 treatments with medication, for metastatic breast cancer
•
have received the following treatments: Herceptin® (trastuzumab), Perjeta® (pertuzumab), andKadcyla®(ado-trastuzumabemtansine)